menu
    • menu
    [{"orgOrder":0,"company":"Gate Neurosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Apimostinel","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase I","graph3":"Gate Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Gate Neurosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gate Neurosciences \/ Not Applicable"},{"orgOrder":0,"company":"Gate Neurosciences","sponsor":"University of Pittsburgh","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Apimostinel","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II","graph3":"Gate Neurosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"","sponsorNew":"Gate Neurosciences \/ University of Pittsburgh","highestDevelopmentStatusID":"8","companyTruncated":"Gate Neurosciences \/ University of Pittsburgh"}]

    Find Clinical Drug Pipeline Developments & Deals for Apimostinel

    Menu

    Apimostinel

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Gate Neurosciences

                            U.S.A arrow
                            IMCAS World Congress
                            Not Confirmed

                            Gate Neurosciences

                            U.S.A arrow
                            IMCAS World Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apimostinel

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase II

                            Sponsor : University of Pittsburgh

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Gate Neurosciences, Pittsburgh Partner for Apimostinel Digital Depression Trial

                            Details : The collaboration aims the initiation of a Phase 2 to assess the potential for extending the efficacy of GATE-202 (apimostinel), a rapid-acting antidepressant drug.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 03, 2024

                            Lead Product(s) : Apimostinel

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase II

                            Sponsor : University of Pittsburgh

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Gate Neurosciences

                            U.S.A arrow
                            IMCAS World Congress
                            Not Confirmed

                            Gate Neurosciences

                            U.S.A arrow
                            IMCAS World Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apimostinel

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Gate Neurosciences Doses First Subject in a Translational EEG Biomarker Study of Apimostinel, a Rapid-Acting T...

                            Details : GATE-202 (apimostinel) is 2nd generation rapid-acting injectable NMDAR modulator program. Previously demonstrated rapid and robust 24-hour antidepressant effects in a Phase 2a MDD study (p=0.0034)

                            Brand Name : GATE-202

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 29, 2022

                            Lead Product(s) : Apimostinel

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth